Alicia Morgans, MD, MPH, Discusses How a Hypothetical Trial Cohort Demonstrates Impacts of Cabazitaxel Costs/Complications in mCRPC

Video

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to discuss how a hypothetical cohort from the CARD trial highlighted the impact of treatment with cabazitaxel on costs and complications in patients with metastatic castration-resistant prostate cancer.

At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of Survivorship Program at Dana-Farber Cancer Institute, about a hypothetical cohort included in the phase 4 CARD trial (NCT02485691).

In addition to highlighting how findings from the cohort shed light on the impact of cabazitaxel (Jevtana) on the costs and complications that patients with metastatic castration-resistant prostate cancer may experience, as well as utilizing this information to better help patients.

Transcript:

We did observe that patients who were treated with cabazitaxel had fewer skeletal-related events, which was very important. The CARD study showed the differences in safety, and in this hypothetical cohort, what we did was apply the differences that already existed within that phase 4 trial to a population of patients. [This was] not to look for new differences, but to understand how that would impact patients in terms of hospital days, ICU days, and cost of care. We weren’t redefining rates of complication, but really taking the known rates from the trial and putting them into context in this setting.

Reference

Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract 587P.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content